stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Shares outstanding
QIAGEN N.V.'s shares outstanding at the end of fiscal 2025 was $218.9M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $207.8M. Over the past ten years it has ranged from $203.2M (fiscal 2019) to $230.6M (fiscal 2023); the current reading is higher than 82% of that period. QIAGEN N.V. ranks 7th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $218.9M | (2.60%) |
| FY2024 | $224.7M | (2.56%) |
| FY2023 | $230.6M | 8.50% |
| FY2022 | $212.6M | 2.25% |
| FY2021 | $207.9M | (0.93%) |
| FY2020 | $209.8M | 3.28% |
| FY2019 | $203.2M | (2.86%) |
| FY2018 | $209.1M | 0.19% |
| FY2017 | $208.7M | (2.50%) |
| FY2016 | $214.1M | 0.14% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $207.8M | (0.53%) |
| Mar 2026 | $208.9M | (4.54%) |
| Dec 2025 | $218.9M | 5.47% |
| Sep 2025 | $207.5M | (4.88%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| QGEN QIAGEN N.V. | $207.8M |
| GH Guardant Health, Inc. compare | $134.4M |
| RVTY Revvity Inc. compare | $111.8M |
| RDNT RadNet, Inc. compare | $78.7M |
| ICLR ICON PLC compare | $77.4M |
| BLLN BillionToOne, Inc. compare | $53.7M |
| CRL Charles River Laboratories International, Inc. compare | $48.6M |
| GRAL GRAIL, Inc. compare | $46.8M |
| MEDP Medpace Holdings, Inc. compare | $28.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement